Neurotrope, Inc.
DelistedCIK 1513856fmd_1XK9C6Z4VF9WHSR7494B85WEMKManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Feb 01, 2010 to Sep 30, 2020, 42 periods
Latest annual · FY2019
Millions- Net income
- (15)
- Free cash flow
- (12)
Latest quarter · Q3 FY2020
Millions- Net income
- (4)
- Free cash flow
- (3)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2014 to FY2019
- n/m
Neurotrope, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2019 | FY2018 | Change | Source |
|---|---|---|---|---|
| Net income | -$15.1 million | -$11 million | 10-K 2020-03-13 · proof | |
| Cash from operating activities | -$11.9 million | -$7.7 million | 10-K 2020-03-13 · proof | |
| Free cash flow | -$11.9 million | -$7.7 million | 10-K 2020-03-13 · proof | |
| Total assets | $17.9 million | $29.5 million | -39.3% | 10-K 2020-03-13 · proof |
| Total liabilities | $479,056 | $3 million | -83.8% | 10-K 2020-03-13 · proof |
| Cash and cash equivalents | $17.4 million | $28.9 million | -39.8% | 10-K 2020-03-13 · proof |
- What was Neurotrope, Inc.'s net income in fiscal 2019?
- Neurotrope, Inc. reported net income of -$15.1 million for fiscal 2019 (the year ended Dec 31, 2019), against -$11 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
- What was Neurotrope, Inc.'s cash from operating activities in fiscal 2019?
- Neurotrope, Inc. reported cash from operating activities of -$11.9 million for fiscal 2019 (the year ended Dec 31, 2019), against -$7.7 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
- What was Neurotrope, Inc.'s free cash flow in fiscal 2019?
- Neurotrope, Inc. reported free cash flow of -$11.9 million for fiscal 2019 (the year ended Dec 31, 2019), against -$7.7 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
- What are Neurotrope, Inc.'s total assets?
- As of Dec 31, 2019, Neurotrope, Inc. reported total assets of $17.9 million, against $29.5 million a year earlier (-39.3%). Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
- What are Neurotrope, Inc.'s total liabilities?
- As of Dec 31, 2019, Neurotrope, Inc. reported total liabilities of $479,056, against $3 million a year earlier (-83.8%). Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
- What are Neurotrope, Inc.'s cash and cash equivalents?
- As of Dec 31, 2019, Neurotrope, Inc. reported cash and cash equivalents of $17.4 million, against $28.9 million a year earlier (-39.8%). Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1513856&period_type=annual&limit=5"Information only, not investment advice.